Prescribing companion
Tarpeyo (budesonide delayed-release capsules) Tarpeyo dosing, the 9-month course and taper, monitoring and prior authorization criteriaFor prescribers and their offices treating IgA nephropathy: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
Tarpeyo Touchpoints enrollment form signed by patient and prescriber, hepatitis B screen, and the prescription routed to PANTHERx Rare Pharmacy, the only dispensing pharmacy.
Example PA threshold
Express Scripts example: biopsy, proteinuria 0.5g a day or UPCR 0.8g/g or higher, 90 days at the maximum tolerated ACEi or ARB dose, eGFR 30 or higher, no prior course.
Monitoring
No REMS and no gated lab; the label asks for hepatitis B screening before starting, monitoring of the conditions a corticosteroid can worsen, and a 2-week taper to 8mg a day at the end of the 9-month course.
Support line
Tarpeyo Touchpoints, 1-833-444-8277, Care Navigator, copay assistance to $0 for commercial plans, delivery through PANTHERx with refill calls.
Before the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enrollment form | The Tarpeyo Touchpoints enrollment form carries both signatures. It starts the financial help search and routes the prescription to PANTHERx Rare Pharmacy. A prescription sent elsewhere is a routing problem, not a denial. | Tarpeyo Touchpoints |
| Hepatitis B screen | The label says to screen for hepatitis B before starting, because a corticosteroid can reactivate a latent infection. | FDA label |
| Infection review | The label says to avoid Tarpeyo in active or latent tuberculosis, untreated fungal, bacterial or viral infection, and ocular herpes simplex, and to rule out certain parasitic infections in patients who have spent time in the tropics. | FDA label |
| Conditions a steroid worsens | The label asks prescribers to monitor patients with hypertension, prediabetes or diabetes, osteoporosis, peptic ulcer, glaucoma or cataracts, or a family history of diabetes or glaucoma. | FDA label |
| Vaccine timing | The label says corticosteroids may reduce the response to some vaccines and asks prescribers to advise on timing. Calliditas states no immunization is required before treatment. | FDA label |
| Prior authorization | The office supplies the biopsy and proteinuria records while Touchpoints looks for financial help. The Care Navigator calls the patient from 1-833-444-8277 to set the first delivery once the form is in. | Tarpeyo Touchpoints |
Prior authorization criteria and what to document
One public policy as the example: Express Scripts, January 29, 2025. Approval 10 months in total. A patient already on Tarpeyo is approved for the months left to reach 10. This policy was reviewed in January 2025 and lowered its protein threshold from the 2024 version. Other plans set their own thresholds and several revised them in 2025 and 2026, so yours may differ. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | IgA nephropathy confirmed by biopsy, age 18 or older | Pathology report with date | Express Scripts policy |
| Proteinuria | 0.5g a day or more, or UPCR 0.8g/g or higher, in the January 2025 policy, lowered from 2024 | Urine protein or UPCR result with date | Express Scripts policy |
| RAS blockade | At least 90 days at the maximum tolerated dose of an ACE inhibitor or ARB | Agent, dose and start date | Express Scripts policy |
| Supportive care | At least 90 days of blood pressure control, lifestyle and cardiovascular risk measures | Blood pressure readings and the dated plan | Express Scripts policy |
| Kidney function | eGFR 30 or higher | Creatinine and eGFR with date | Express Scripts policy |
| Treatment history | No previous course of Tarpeyo; a patient mid-course is approved for the months left to reach 10 | Start date of the current course if this is a continuation | Express Scripts policy |
| Prescriber | Prescribed by or in consultation with a nephrologist | Specialty on the request, or the consult note | Express Scripts policy |
Tarpeyo dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | 16mg once daily as four 4mg delayed-release capsules, in the morning, at least 1 hour before a meal, swallowed whole; never opened, crushed or chewed. A 120-capsule bottle is a 30-day supply. | FDA label |
| Months 1 to 9 | 16mg once daily. The label's course is 9 months. | FDA label |
| Final 2 weeks | Taper to 8mg once daily for the last 2 weeks of the course. The label's adrenal suppression warning is the reason the course is not stopped abruptly. The safety and benefit of a second course have not been established. | FDA label |
| Missed dose | Take the prescribed dose at the next scheduled time; do not double. | FDA label |
Monitoring the Tarpeyo label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Baseline | Hepatitis B screen; blood pressure; glucose where there is diabetes, prediabetes or a family history; bone and eye history | The label lists these as conditions to monitor rather than contraindications | FDA label |
| Week 2 onward | Hypercorticism: edema, hypertension, acne, muscle cramps | Peripheral edema occurred in 17% against 5% on placebo and hypertension in 12% against 3%; most reversed after the course | FDA label |
| Any time | Infection | The label says a corticosteroid can mask or cause infection and asks prescribers to consider stopping the drug if one develops; varicella and measles exposure is a same-day report | FDA label |
| Surgery or severe stress | Adrenal suppression | The label says a patient on a corticosteroid may need supplemental steroid during surgery or other severe stress | FDA label |
| At the taper and after | Fatigue, weakness, hypotension | Signs of adrenal suppression when the course ends | FDA label |
Tarpeyo drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Avoid | Strong CYP3A4 inhibitors: ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, cyclosporine | FDA label |
| Avoid | Grapefruit and grapefruit juice for the whole course | FDA label |
| Pregnancy | The Patient Information says Tarpeyo may harm an unborn baby; the label does not require contraception; infants exposed in utero are observed for hypoadrenalism | FDA label |
Why a first fill stalls, and the fix
- The prescription went to a retail or other specialty pharmacyOnly PANTHERx Rare Pharmacy dispenses Tarpeyo. The enrollment form routes it there, and the prescriber's office can resend a stray prescription. This is a routing problem, not a denial.
- Prior authorization not yet approvedThe insurer wants the criteria below documented, most often the biopsy, a protein measurement, and 90 days at the highest tolerated dose of an ACE inhibitor or ARB. The nephrologist's office supplies the records.
- The plan says you have had Tarpeyo beforePolicies approve one course of about 10 months and ask that the patient has not been treated with Tarpeyo before, because the label has not established a second course. If this is a continuation of an interrupted first course, the prescriber's records showing the dates settle it.
- A copay you cannot payCommercial insurance: the Tarpeyo Touchpoints copay program, which can bring the cost to $0 for eligible patients. The program's eligibility rules name commercial insurance only, so people on Medicare or Medicaid need other help, and our help paying page lists which charity funds are open.
Tarpeyo Touchpoints
- A Care Navigator who looks for financial help you qualify for, schedules the first delivery and calls before each refill
- Copay assistance that can bring the cost to $0 for eligible US residents with commercial insurance, by the program's own terms
- Home delivery through PANTHERx Rare Pharmacy, with email tracking and optional text reminders for refills
- A Touchpoints pharmacist who checks in during the 9-month course to answer questions about the drug
Questions prescribers' offices ask about Tarpeyo
What is the Tarpeyo dose and how long is the course?
16mg once daily as four 4mg capsules in the morning, at least 1 hour before a meal, for 9 months, then 8mg once daily for the final 2 weeks. The January 2026 label says the safety and benefit of a second course have not been established.
Is there a REMS for Tarpeyo?
No. There is no REMS and no lab that gates dispensing, but the label asks prescribers to screen for hepatitis B before starting and to monitor patients with hypertension, diabetes, osteoporosis, peptic ulcer, glaucoma or cataracts.
Which pharmacy dispenses Tarpeyo?
PANTHERx Rare Pharmacy is the only dispensing pharmacy. The Tarpeyo Touchpoints enrollment form, signed by patient and prescriber, routes the prescription there.
What do insurers ask for to approve Tarpeyo?
The January 2025 Express Scripts policy shown on this page asks for biopsy-confirmed IgA nephropathy, proteinuria of 0.5g a day or more or UPCR of 0.8g/g or higher, 90 days at the maximum tolerated ACEi or ARB dose, eGFR of 30 or higher, no previous course, and a nephrologist. It approves 10 months in total.
Which drugs interact with Tarpeyo?
The label says to avoid strong CYP3A4 inhibitors, naming ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin and cyclosporine, and grapefruit for the whole course.
Sources
- TARPEYO (budesonide) prescribing information and Patient Information, sections 2, 5, 6, 7, 16 and 17, revised January 2026, Calliditas Therapeutics, via openFDA and DailyMed, 2026-01-21.
- NDA 215935/S-005 supplement approval letter, Warnings and Precautions 5.2, FDA, 2024-06-05.
- TARPEYO Savings, Copay Support & Financial Assistance, and Starting TARPEYO, Calliditas Therapeutics, 2026-10-01.
- Nephrology, Tarpeyo Prior Authorization Policy, Express Scripts, 2025-01-29.
A reference drawn from the January 21, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Not a treatment recommendation and not a substitute for the prescribing information. Trial Friend takes no money from any drugmaker, pharmacy, insurer or program named here.